1808 related articles for article (PubMed ID: 17576936)
1. Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis.
Ziemer M; Wiesend CL; Vetter R; Weiss J; Blaschke S; Norgauer J; Mockenhaupt M
Arch Dermatol; 2007 Jun; 143(6):711-6. PubMed ID: 17576936
[TBL] [Abstract][Full Text] [Related]
2. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
[TBL] [Abstract][Full Text] [Related]
3. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A
Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941
[TBL] [Abstract][Full Text] [Related]
4. [Severe skin reactions. Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema exsudativum multiforme majus and generalized bullous fixed drug exanthema].
Rzany B; Mockenhaupt M; Baur S; Stocker U; Schöpf E
Hautarzt; 1993 Aug; 44(8):549-54; quiz 554-6. PubMed ID: 8376113
[No Abstract] [Full Text] [Related]
5. [Stevens-Johnson syndrome and toxic epidermal necrolysis following intake of sulfonamides].
Aberer W; Stingl G; Wolff K
Hautarzt; 1982 Sep; 33(9):484-90. PubMed ID: 7174320
[TBL] [Abstract][Full Text] [Related]
6. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective.
Mockenhaupt M; Kelly JP; Kaufman D; Stern RS;
J Rheumatol; 2003 Oct; 30(10):2234-40. PubMed ID: 14528522
[TBL] [Abstract][Full Text] [Related]
7. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.
Roujeau JC; Kelly JP; Naldi L; Rzany B; Stern RS; Anderson T; Auquier A; Bastuji-Garin S; Correia O; Locati F
N Engl J Med; 1995 Dec; 333(24):1600-7. PubMed ID: 7477195
[TBL] [Abstract][Full Text] [Related]
8. Anaphylaxis and toxic epidermal necrolysis or Stevens-Johnson syndrome after nonmucosal topical drug application: fact or fiction?
Sachs B; Fischer-Barth W; Erdmann S; Merk HF; Seebeck J
Allergy; 2007 Aug; 62(8):877-83. PubMed ID: 17620064
[TBL] [Abstract][Full Text] [Related]
9. Valdecoxib-associated acute generalized exanthematous pustulosis.
Byerly FL; Nelson KC; Granko RP; Morrell DS; Cairns BA
Burns; 2005 May; 31(3):383-7. PubMed ID: 15774300
[TBL] [Abstract][Full Text] [Related]
10. [Cutaneous reactions to drugs].
Mulder WM; Meinardi MM; Bruynzeel DP
Ned Tijdschr Geneeskd; 2004 Feb; 148(9):415-20. PubMed ID: 15038200
[TBL] [Abstract][Full Text] [Related]
11. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis.
Rzany B; Hering O; Mockenhaupt M; Schröder W; Goerttler E; Ring J; Schöpf E
Br J Dermatol; 1996 Jul; 135(1):6-11. PubMed ID: 8776350
[TBL] [Abstract][Full Text] [Related]
12. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome.
Harr T; French LE
Med Clin North Am; 2010 Jul; 94(4):727-42, x. PubMed ID: 20609860
[TBL] [Abstract][Full Text] [Related]
13. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature.
Letko E; Papaliodis DN; Papaliodis GN; Daoud YJ; Ahmed AR; Foster CS
Ann Allergy Asthma Immunol; 2005 Apr; 94(4):419-36; quiz 436-8, 456. PubMed ID: 15875523
[TBL] [Abstract][Full Text] [Related]
14. [Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs)].
Boehncke S; Boehncke WH
Dtsch Med Wochenschr; 2005 Oct; 130(40):2249-52. PubMed ID: 16208597
[TBL] [Abstract][Full Text] [Related]
15. A 2-year-old girl with Stevens--Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulin.
Arca E; Köse O; Erbil AH; Nişanci M; Akar A; Gür AR
Pediatr Dermatol; 2005; 22(4):317-20. PubMed ID: 16060867
[TBL] [Abstract][Full Text] [Related]
16. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations.
Teraki Y; Shibuya M; Izaki S
Clin Exp Dermatol; 2010 Oct; 35(7):723-8. PubMed ID: 19874350
[TBL] [Abstract][Full Text] [Related]
17. Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Fujita Y; Yoshioka N; Abe R; Murata J; Hoshina D; Mae H; Shimizu H
J Am Acad Dermatol; 2011 Jul; 65(1):65-8. PubMed ID: 21507517
[TBL] [Abstract][Full Text] [Related]
18. Assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP).
Boccia R; Anné PR; Bourhis J; Brizel D; Daly C; Holloway N; Hymes S; Koukourakis M; Kozloff M; Turner M; Wasserman T
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):302-9. PubMed ID: 15337569
[TBL] [Abstract][Full Text] [Related]
19. Drug rash with eosinophilia and systemic symptoms vs toxic epidermal necrolysis: the dilemma of classification.
Wolf R; Matz H; Marcos B; Orion E
Clin Dermatol; 2005; 23(3):311-4. PubMed ID: 15896547
[TBL] [Abstract][Full Text] [Related]
20. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.
Bastuji-Garin S; Rzany B; Stern RS; Shear NH; Naldi L; Roujeau JC
Arch Dermatol; 1993 Jan; 129(1):92-6. PubMed ID: 8420497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
